🔗 Share this article

An underground economy for unlicensed slimming drugs is propelled by social media fitness personalities and sellers on messaging platforms, based on new investigations.

Experimental Treatment Gaining Popularity Via Social Media

Retatrutide, which is still in clinical trials, is being advertised by social media influencers for its supposed fat-burning properties. Followers are encouraged to message these profiles directly for source information, while also receiving promotional offers.

Thriving Commerce on Social Networks

Separately, a robust market exists on Telegram, where communities with numerous of members share “before and after” images, injection guides and claims of rapid British shipping. Sellers market the substance there before redirecting customers to other platforms for purchases.

Learning About The Experimental Drug

This medication is an investigational injectable developed by US drugmaker Eli Lilly. The treatment targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help patients lose up to 25% of their total weight. Nicknamed the “triple G”, the substance is being promoted digitally as the successor to Ozempic.

Healthcare Experts Voice Worries

However, physicians and pharmacists have cautions that the sale of what is still an unapproved drug in the UK is worrisome and could lead to users injecting products of uncertain source.

Several professionals said the popularity for the experimental drug could be linked to the rising cost of licensed slimming products such as Mounjaro.

Legal Status and Implementation

Marketing retatrutide on TikTok or Telegram is illegal in the United Kingdom, as it is an unapproved drug that cannot be promoted or supplied for personal consumption under the British medical regulations.

Several content creators attempt to circumvent the rules by referring to the drug as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted drug, but advertising and supply can still breach pharmaceutical, advertising, and consumer laws, potentially leading to fines, prosecution or imprisonment.

Platform Response and Content Removal

Based on the social media company, the service has taken down problematic material and banned related hashtags and query recommendations. The company said it was committed to keeping the platform secure and investing in strengthening compliance measures.

Online Trading Activities

Research also discovered communities with up to 9,000 participants selling retatrutide using Telegram's built-in search feature, which functions like a online catalog. Typing “retatrutide” instantly brings up channels with numerous of members, filled with images of weight loss, glowing testimonials and step-by-step guides for preparing or injecting at residence.

After minutes of entering one group, a seller posted WhatsApp details, where the majority of purchases occur. The seller provided an guidebook and promised delivery within 48 hours. When asked whether the product was authentic, one vendor said: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. None asked about body mass, health issues or past usage.

Product Details and Pricing

Inside these groups, messages display black plastic packages with postal service labels, claiming to include new batches. One communication read: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, prepared at home with sterile water, or ready-to-use pens typically sold at £160 for 20 milligrams. When questioned how much time a pen should last, sellers give contradictory answers varying between a several days to “depends on your body”.

Platform Oversight and Safety Measures

A spokesperson for Telegram stated it regularly monitored dangerous content on its platform including content that promoted the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Medical Expert Warnings

“Individuals are injecting substances they can’t verify. Although the science behind retatrutide is sound, these digital versions may not contain what they claim,” said a pharmacy expert, the head of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of an online medical service linked the surge in demand to recent cost increases for approved weight-loss drugs such as Mounjaro. “With prices increasing, patients are turning to online platforms. But counterfeit treatments are highly risky. You cannot know what’s contained or whether the environment they were produced in was clean,” she explained.

Her staff has already encountered individuals injured by self-injection from unverified sources. “We recognize the disappointment, but purchasing from messaging apps or communication platforms is taking chances with your well-being,” said the doctor. “These materials could be impure or incorrectly dosed.”

Producer Position

A spokesperson from Eli Lilly said retatrutide was in third stage clinical trials and had not been evaluated or authorized by any regulatory agency anywhere in the world. “Therefore at this time no one can sell [it] for personal consumption,” they said, noting that any product “misleadingly claiming itself as a company experimental substance not yet authorized … may expose patients to possibly serious medical dangers”.